Stocks · News reference
Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28
Deutsche Bank analyst David Hoang initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $28.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Adjusts Price Target on Climb Bio to $27
Wedbush Securities maintained an 'Outperform' rating on Climb Bio and increased its price target for the company's stock from $25 to $27.
Climb Bio Reports Third Quarter 2026 Financial Results
Climb Bio, Inc. announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline.
8-K filing — Climb Bio, Inc. (CLYM)
Filed: 2026-11-05 AccNo: 0001193125-26-448556 Size: 27 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Climb Bio to Present New Clinical Data for Budoprutug at ASH 2026
Climb Bio, Inc. announced it will present new clinical data for its anti-CD19 monoclonal antibody, budoprutug, at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2026.
Climb Bio To Present New Clinical Data For Budoprutug In Immune Thrombocytopenia At 68th ASH Annual Meeting And Exposition